{
    "nct_id": "NCT04419623",
    "official_title": "A Phase 1/2, Double-Blind, Randomized, Placebo-Controlled Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer",
    "inclusion_criteria": "* Known diagnosis of active cancer that is not considered cured or disease free.\n* Confirmed COVID-19 infection as per World Health Organization (WHO) criteria with suspected pneumonia requiring hospitalization and oxygen saturation < 94% on room air or requires supplemental oxygen.\n* Adequate hematological, hepatic and renal function as would be medically expected of a cancer patient population.\n* Able to swallow and absorb oral medications.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Current active treatment with medications contraindicated for receipt of investigational product.\n* Require chemotherapy or urgent systemic therapy for active cancer that cannot be withheld.\n* No remaining available therapies for advanced or metastatic malignancies.\n* Participation in another clinical study with therapeutic intent for COVID-19\n* Require artificial ventilation at screening.\n* Life expectancy less than 6 months.\n* Medical conditions that make it unsafe to receive investigational product (for example, heart attack in the last 6 mos, unstable angina, uncontrolled arrhythmia, heart failure class 3/4, QTC interval > 480 msec; known bleeding disorders, stroke or intracranial hemorrhage in the last 6 mos; active HBV, HCV or history of HIV; GI malabsorption syndrome, small bowel resection, poorly controlled IBS; untreated/actively progressing known CNS lesions).\n* Receipt of radiation therapy to the lung or mediastinum for treatment of COVID-19",
    "miscellaneous_criteria": ""
}